List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 7 studies with search of:   "Biocine" [Exact]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: MTP-PE/MF59
2 Completed A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2
3 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 Mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
4 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1 SF-2
5 Completed A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)
Condition: HIV Infections
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3
6 Completed A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: MTP-PE/MF59;   Biological: Env 2-3
7 Active, not recruiting A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: Placebo version of rgp120/HIV-1MN;   Biological: Placebo version of rgp120/HIV-1SF2

  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services